SYS6043

Phase 3Small molecule

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

SYS6043 is one of 84 small molecule programs targeting Platinum-resistant Ovarian Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Platinum-Resistant Ovarian CancerNot yet recruiting

Advanced/metastatic Solid TumorsRecruiting

Advanced Solid TumorsRecruiting

Platinum-Resistant Ovarian CancerPhase 3

Not yet recruiting

Advanced/metastatic Solid TumorsPhase 2

Recruiting

Advanced Solid TumorsPhase 2

Recruiting

Competition

Competitive Landscape

311 competitors in Advanced Solid Tumors

#DrugCompanyPhaseTrials

Opdivo

Bristol-Myers Squibb

Phase 2

19 2

Fludara

Sanofi

Phase 2

16 3

Avastin

Roche

Phase 2

15 4

Paraplatin

AAvyxa

Phase 2

32 5

Abraxane

Bristol-Myers Squibb

Phase 2

11 6

Imfinzi

AstraZeneca

Phase 2

10 7

Cytoxan

BBaxter Healthcare Corporation

Phase 2

19 8

Lenvima

Eisai

Phase 2

5 9

Libtayo

Regeneron

Phase 2

4 10

Braftovi

Pfizer

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 1/2Recruiting

Advanced/metastatic Solid Tumors

NCT07415863

Q4 2028

Phase 1/2Recruiting

Advanced Solid Tumors

NCT07241936

Q2 2030

Phase 1Recruiting

Advanced/metastatic Solid Tumors

NCT07424547

Q4 2030

Phase 3Not yet recruiting

Platinum-Resistant Ovarian Cancer

NCT07708753

Clinical

Trials by Indication[1]

Advanced/Metastatic Solid Tumors2 trials

Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors

Recruiting·CConjupro Biotherapeutics, Inc.·Phase 1·NCT07424547·386 enrolled

Phase 1/II Clinical Study of SYS6043 in the Treatment of Advanced/Metastatic Solid Tumors

Recruiting·CCSPC Megalith Biopharmaceutical Co.,Ltd.·Phase 1/2·NCT07415863·820 enrolled

Advanced Solid Tumors1 trial

A Study of Sirolimus (Albumin-Bound) in Combination With Different ADCs Treatment of Advanced Solid Tumors

Recruiting· CSPC ZhongQi Pharmaceutical Technology Co., Ltd. logo

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 1/2·NCT07241936·444 enrolled

Platinum-resistant Ovarian Cancer1 trial

A Randomized, Multicenter, Open-label, Phase 3 Clinical Trial Evaluating SYS6043 Versus Investigator's Choice Chemotherapy in Participants With Platinum-resistant Advanced Ovarian Cancer, Primary Peritoneal Cancer, and Fallopian Tube Cancer.

Not yet recruiting·CCSPC Megalith Biopharmaceutical Co.,Ltd.·Phase 3·NCT07708753·460 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for SYS6043. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SYS6043 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SYS6043. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — CSPC ZhongQi Pharmaceutical Technology Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

SYS6043

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Q4 2028

Q2 2030

Q4 2030

Trials by Indication[1]

Advanced/Metastatic Solid Tumors2 trials

Advanced Solid Tumors1 trial

Platinum-resistant Ovarian Cancer1 trial

References

Drug Info

Quick Facts

Related News